HOME >> MEDICINE >> NEWS
SKCC's Gennadi Glinsky addresses predicting risk in cancer treatment outcome

-up a clinical trial to evaluate the utility of a genetic test measuring the expression profiles of the 11-gene signature as a prognostic and therapy outcome marker.

Gennadi Victor Glinsky, M.D., Ph.D.

Gennadi Victor Glinsky, M.D., Ph.D., is an associate professor at the Sidney Kimmel Cancer Center in San Diego. He is also a consultant for the National Institutes of Health and serves on the National Cancer Institute Review Panels.

Dr. Glinsky holds membership to numerous professional organizations such as the American Association for the Advancement of Science, the American Association for Cancer Research and the Metastasis Research Society. Dr. Glinsky serves as a reviewer for various journals including the Lancet, Journal of Clinical Investigation, Cancer Research, American Journal of Pathology and Oncogene.

Dr. Glinsky earned a doctor of medicine in internal medicine and general pathology. He later received his doctorate in experimental oncology and biochemistry from the Institute of Oncology Problems Academy of Sciences of Ukraine in Kiev.


'"/>

Contact: Jay Jeffcoat
jjeffcoat@skccfoundation.org
858-410-4212
Sidney Kimmel Cancer Center
18-Apr-2005


Page: 1 2

Related medicine news :

1. Asia-European collaboration addresses water management in Indonesia
2. New technology addresses female fertility preservation
3. New research addresses taboos around the impact of rheumatoid arthritis on patients sex lives
4. Friedman addresses UN-sponsored African workshop on E-Governance
5. New handbook addresses lesbian, gay, bisexual and transgender health issues
6. UK addresses funding gap created by US anti-abortion stance
7. New pediatrician workforce policy addresses growing challenges in health care
8. Child magazine editor addresses regions first annual womens and childrens health care conference
9. Why predicting the next influenza pandemic is difficult and how scientists can best prepare
10. Repeat bone mineral density scans do not appear helpful for predicting fractures in most older women
11. HIV measurement appears to be less reliable than thought in predicting loss of CD4 cells

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/22/2017)... ... September 22, 2017 , ... ... other tick-borne diseases through research, education and awareness, today announced the appointment of ... immunologist and microbiologist, Dr. Sellati has more than 20 years of research experience ...
(Date:9/21/2017)... ... ... 38-Year-Old Plastic Surgeon Gill at Aesthetic Surgery Center is Saluted as Young ... Plastic Surgeon Kiranjeet Gill has been awarded as one of the 15th annual 40-under-40 ... was started in 2003 to salute young achievers in Southwest Florida who have distinguished ...
(Date:9/21/2017)... ... 2017 , ... SABRE is raising awareness about personal safety with a Chicago ... November. , The Chicago, Illinois, based self-defense brand has been waiting for an opportunity ... of taking their personal safety into their own hands. , The ads focus on ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... Management Report**, http://www.fdanews.com/products/54818-promotional-communication      , In the competitive world of drug and ... while staying in compliance with FDA rules. , The FDA has issued two ...
(Date:9/21/2017)... ... September 21, 2017 , ... Demonstrating a consistent and ... departments have been awarded five-year accreditation status through the Public Health Accreditation ... served by a PHAB-accredited health department now extend to more than 203 ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... BOTHELL, Wash. , Sept. 7, 2017   BioLife ... developer, manufacturer and marketer of proprietary clinical grade cell and ... media ("BioLife"), announces that Mike Rice , President and ... Rodman & Renshaw 19 th ... 3:25 p.m. Eastern time (12:25 p.m. Pacific time). The conference ...
(Date:9/6/2017)... 2017 Eli Lilly and Company (NYSE: ... data for galcanezumab and lasmiditan, two investigational treatments for ... Society (IHC) taking place Sept. 7-10 in ... new, long-term data from an open-label study evaluating the ... mg and 240 mg) for the prevention of migraine. ...
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ... on the development of oral drug delivery systems, announced ... the U.S. Food and Drug Administration (FDA) regarding ORMD-0801, ... At the meeting, the FDA gave ... ORMD-0801, would be a Biologics License Application (BLA).  Such ...
Breaking Medicine Technology:
Cached News: